Can an Anti-Inflammatory drug shield the brain after a bleeding stroke?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent * Age: 18-85 years * Weight\> 50 kg * Spontaneous SAH diagnosed on a native CT brain max. 48 hours after the first symptoms * Spontaneous SAH caused by rupture of the cerebral aneurysm confirmed on DSA or CT angiography (Fisher grade 1 to 4) OR Spontaneous SAH without a source on CT AG, DSA or MRI with Fisher grade 3 and 4 * For women capable of becoming pregnant (see definitions from the CTFG guideline for contraception): use of the following highly reliable contraceptive method within 3 months after the end of the study: adherence to sexual abstinence or contraception containing progesterone with inhibition of ovulation (oral administration, injection) or non-hormonal intrauterine device or hormonal or bilateral tubal occlusion or partner vasectomy. Males: adherence to sexual abstinence or use of an adequate contraceptive method (i.e. condom) in case of sexual intercourse within 3 months after the end of the study. Exclusion Criteria: * Symptoms of SAH without the finding of blood on the initial native CT scan of the brain * SAH from a cause other than a ruptured aneurysm, e.g. A-V malformation, traumatic SAH * Pregnancy and breastfeeding (pregnancy test) * Known hypersensitivity to the components of the product * Allergic reaction to the active substance or sulfonamides in the anamnesis * Concomitant treatment with other non-steroidal anti-inflammatory drugs, aspirin or corticosteroids (at least five half-lives before administration of the medicinal product under investigation) * Severe hepatic insufficiency (serum albumin level \<25 g/l or Child-Pugh score less than 10). * Active peptic ulcer or bleeding from the gastrointestinal tract in the anamnesis * Inflammatory bowel disease in the anamnesis * Congestive heart failure (NYHA II-IV) in history. * Proven ischemic heart disease, peripheral arterial insufficiency. * Participation in another clinical study (a gap of at least five half-lives before administration of the medicinal product under investigation).